Feedback PLC Pilot Scheme with Sussex Integrated Care System (4300P)
19 Oktober 2021 - 8:00AM
UK Regulatory
TIDMFDBK
RNS Number : 4300P
Feedback PLC
19 October 2021
Prior to publication, the information contained within this
announcement was deemed by the Company to constitute inside
information as stipulated under the Market Abuse Regulations (EU)
No. 596/2014 ("MAR"). With the publication of this announcement,
this information is now considered to be in the public domain.
Feedback plc
Pilot Scheme with Sussex Integrated Care System to install
Bleepa and CareLocker in Community Diagnostic Centres
-- Pilot to be conducted with Queen Victoria Hospital NHS
Foundation Trust (QVH) on behalf of Sussex Integrated Care System
(Sussex ICS)
-- Pilot to use Bleepa and CareLocker as a digital
infrastructure to facilitate patient specific pathways through the
Community Diagnostic Centres (CDC), linking both primary and
secondary care settings
-- GBP10bn CDC initiative announced by NHS England as a
nationwide initiative and represents a significant commercial
opportunity for Feedback
-- CDC programme requires a secure, effective system of
integrated clinical communication and secure individual patient
records access to permit seamless data access across NHS
constituents and CDCs: Feedback is well positioned to meet these
needs through its recently launched clinical communication products
and experience
London, 19 October 2021 : Feedback plc (AIM: FDBK, "Feedback" or
the "Company"), the specialist clinical communication company,
announces that it has entered into a memorandum of understanding
(MOU) to embark on a pilot scheme to provide CDC services with
Sussex ICS as one of the UK's CDC exemplar sites.
The CDC programme is a GBP10bn programme designed to help reduce
the elective care backlog facing the NHS by bringing diagnostic
investigations closer to patients in community settings. The
programme is aimed at reducing the need for patients to attend
hospital for diagnostic tests, enabling hospital facilities to be
better utilised to manage inpatient and emergency services.[i] CDCs
will provide a range of diagnostic investigations including medical
imaging, blood tests, ECGs and eventually endoscopy services.
The pilot will use Feedback's digital infrastructure which
includes Bleepa and CareLocker with the intention to identify the
specification for bespoke development to meet the core CDC system
needs of Sussex ICS. Feedback's primary product, Bleepa, provides a
digital clinical communication platform to allow these
investigations to be captured, associated with a specific patient
journey and presented to clinicians in both primary and secondary
care settings for review, discussion and planning onward
management. The pathway record will then be stored centrally using
Feedback's patient-specific CareLocker infrastructure to ensure its
onward availability to all care settings.
The pilot is expected to run until March 2022 and will initially
focus on delivering targeted CDC pathways in specific clinical
areas such as respiratory and cardiology. It is anticipated that
more pathways will be added as the pilot progresses with the
ultimate aim of agreeing contractual terms for a commercial
roll-out to CDCs. The terms of the MOU are non-binding.
As one of the first CDC sites to be launched in the UK, this
pilot is expected to act as a blueprint model for how CDCs can be
delivered. For CDCs to deliver their potential in streamlining
patient journeys, accelerating investigation and decision making,
it is essential that CDCs are connected to primary and secondary
care settings and have the right digital infrastructure to present
diagnostic information to these settings whilst facilitating
cross-site communication. The Board believes that Feedback is
uniquely placed to deliver this digital infrastructure through
Bleepa and CareLocker combined given the products' abilities to
share and store medical data and facilitate patient-specific case
discussion across provider settings.
Dr Tom Oakley, CEO of Feedback, said: "The CDC programme sees
the creation of an entirely new care setting and it needs the right
digital infrastructure to ensure that it is fully integrated in
order to deliver the intended system benefits and to drive down the
elective care backlog. This is a once-in-a-generation opportunity
to redesign care pathways and service delivery to our citizens. We
are delighted to be working with such an innovative team across QVH
and the wider Sussex ICS and are proud that Bleepa will feature in
one of the showcases of the CDC programme. Connecting teams across
care settings and presenting clinical data to drive faster decision
making is precisely what Bleepa is designed to deliver. The CDC
programme is an exciting opportunity for us to demonstrate our
technology at a regional level and we believe that this will lead
to a number of broader opportunities for Bleepa and our supporting
technologies within the CDC programme and beyond."
Dr Ian Francis, Deputy Medical Director at QVH said: " We are
very pleased to be working with Feedback and believe that the
Bleepa platform will enable us to deliver cross-regional care
aligned to designated clinical pathways. The patient-centric
approach is core to our CDC proposal and the combination of Bleepa
and CareLocker will allow us to deliver a connected CDC programme
that maximises the impact for staff, patients and the wider
system."
Further information on Bleepa can be found on the Company's
website:
https://fbkmed.com/feedback-plc/reports-and-presentations/
-Ends-
Enquiries:
Feedback plc +44 (0)1954 718072
Tom Oakley, CEO IR@fbk.com
Lindsay Melvin, CFO
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Emma Earl/Freddy Crossley (Corporate
Finance)
Rupert Dearden (Corporate Broking) +44 (0)20 7886 2500
Walbrook PR Ltd Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
Paul McManus/Nick Rome/Nicholas Johnson 07980 541 893 or 07748 325 236
or 07884 664 686
Notes to Editors
Feedback plc (AIM: FDBK) is a pioneer of regulated clinical
communication products. Its core product, Bleepa, is a
revolutionary medical imaging communications app, providing an
easy-to-use, high quality tool to enable remote and secure
communications between front-line clinicians and teams.
Importantly, it is the only CE marked medical imaging
communications platform on the NHSx clinical communications tools
framework. Bleepa has unparalleled functionality for everyday
practice and can be accessed from any internet-connected device,
enabling control of patient cases when on the go.
Its highly scalable Software as a Service ("SaaS") based revenue
model will provide increasing levels of visibility as the Company
grows its customer base. With a growing distribution base and
technology in place, the focus is on leveraging key relationships
in order to drive sales both in the UK and internationally to all
forms of care providers. As a fully certified medical device,
Bleepa aims to disrupt the medical imaging communications market
and, importantly, increase the accuracy and speed of clinical
review.
[i]
https://uk.eu-supply.com/ctm/Supplier/PublicTenders/ViewNotice/26333
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCMPBATMTMBBJB
(END) Dow Jones Newswires
October 19, 2021 02:00 ET (06:00 GMT)
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Feedback (LSE:FDBK)
Historical Stock Chart
Von Jul 2023 bis Jul 2024